Stratification value and application strategies of HPV E6/E7 mRNA testing in cervical cancer screening

doi:10.11958/20260725

Abstract

Abstract:

With the deepening understanding of the pathogenesis of cervical cancer and the development of diverse screening modalities for cervical cancer, the detection of human papillomavirus (HPV) E6/E7 mRNA targets the transcriptional activity of viral oncogenes, directly reflects the carcinogenic potential and viral integration status of HPV, driving a paradigm shift in cervical cancer screening strategies from merely "detecting infection" to precisely "assessing risk". This article systematically reviews the molecular basis, technical characteristics, diagnostic performance and triage application of HPV E6/E7 mRNA testing, explores its value in dynamic monitoring for risk-stratified management of precancerous lesions and the clinical challenges encountered, and provides insights for precision prevention and control of cervical cancer and optimization of healthcare resources.

Key words: papillomaviridae, cervical intraepithelial neoplasia, uterine cervical neoplasms, E6/E7 mRNA, risk stratification

CLC Number:

R711.74

Figures/Tables 1

References 38

[1]	Pruski D, Millert-Kalińska S, Wszołek K, et al. Analysis of molecular markers of HPV infection persistence:a narrative review[J]. Cancers(Basel), 2026, 18(6):981. doi:10.3390/cancers18060981.
[2]	Wang J, Wang L, Bu F, et al. Comparative performance of standalone E6/E7 mRNA testing versus a combined DNA genotyping and viral load assay for detecting cervical high-grade lesions:a retrospective paired study[J]. Am J Transl Res, 2026, 18(1):842-859. doi:10.62347/WNNZ7362.
[3]	Brant A C, Menezes A N, Felix S P, et al. Characterization of HPV integration,viral gene expression and E6E7 alternative transcripts by RNA-Seq:a descriptive study in invasive cervical cancer[J]. Genomics, 2019, 111(6):1853-1861. doi:10.1016/j.ygeno.2018.12.008.
[4]	Zhang Y, Qiu K, Ren J, et al. Roles of human papillomavirus in cancers:oncogenic mechanisms and clinical use[J]. Signal Transduct Target Ther, 2025, 10(1):44. doi:10.1038/s41392-024-02083-w.
[5]	Zhou L, Qiu Q, Zhou Q, et al. Long-read sequencing unveils high-resolution HPV integration and its oncogenic progression in cervical cancer[J]. Nat Commun, 2022, 13(1):2563. doi:10.1038/s41467-022-30190-1.
[6]	Varesano S, Ciccarese G, Paudice M, et al. Evaluating HPV viral load and multiple infections for enhanced cervical cancer risk-based assessment[J]. Life(Basel), 2025, 15(2):153. doi:10.3390/life15020153.
[7]	WHO. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention,second edition[M]. Geneva: World Health Organization, 2021,6-7.
[8]	Kafasi A, Pitiriga V C, Spanakis N, et al. Evaluation of the pretect HPV-proofer E6/E7 mRNA assay for the detection of precancerous cervical lesions in the Greek female population[J]. Pathogens, 2025, 14(9):853. doi:10.3390/pathogens14090853.
[9]	Baranda-Ávila N, Maldonado G, Vélez D E, et al. Translational regulation of human papillomavirus mRNAs in carcinogenesis: old questions and new insights[J]. Front Cell Dev Biol, 2025, 13:1676001. doi:10.3389/fcell.2025.1676001.
[10]	Tian R, Huang Z, Li L, et al. HPV integration generates a cellular super-enhancer which functions as ecDNA to regulate genome-wide transcription[J]. Nucleic Acids Res, 2023, 51(9):4237-4251. doi:10.1093/nar/gkad105.
[11]	Li J, Li S. From viral infection to genome reshaping:The triggering role of HPV integration in cervical cancer[J]. Int J Mol Sci, 2025, 26(18):9214. doi:10.3390/ijms26189214.
[12]	Karimzadeh M, Arlidge C, Rostami A, et al. Human papillomavirus integration transforms chromatin to drive oncogenesis[J]. Genome Biol, 2023, 24(1):142. doi:10.1186/s13059-023-02926-9.
[13]	Han S, Lin M, Liu M, et al. Prevalence,trends,and geographic distribution of human papillomavirus infection in Chinese women:a summative analysis of 2 728 321 cases[J]. BMC Med, 2025, 23(1):158. doi:10.1186/s12916-025-03975-6.
[14]	Zhang J, Cheng K, Wang Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China:a meta-analysis[J]. Arch Gynecol Obstet, 2020, 302(6):1329-1337. doi:10.1007/s00404-020-05787-w.
[15]	Wang M, Liang H, Yan Y, et al. Distribution of HPV types among women with HPV-related diseases and exploration of lineages and variants of HPV 52 and 58 among HPV-infected patients in China:a systematic literature review[J]. Hum Vaccin Immunother, 2024, 20(1):2343192. doi:10.1080/21645515.2024.2343192.
[16]	Boon S S, Xia C, Lim J Y, et al. Human papillomavirus 58 E7 T20I/G63S variant isolated from an East Asian population possesses high oncogenicity[J]. J Virol, 2020, 94(8):e00090-e00020. doi:10.1128/JVI.00090-20.
[17]	Lai T O, Boon S S, Law P T, et al. Oncogenicitiy comparison of human papillomavirus type 52 E6 variants[J]. J Gen Virol, 2019, 100(3):484-496. doi:10.1099/jgv.0.001222.
[18]	Al-Shibli K, Nguyen D T, Mohammed H, et al. Genotype-specific HPV E6/E7 mRNA triage improves risk stratification and reduces referrals in DNA-positive ASC-US/LSIL:a real-world cohort from Nordland,Norway[J]. Pathogens, 2026, 15(2):178. doi:10.3390/pathogens15020178.
[19]	Downham L, Jaafar I, Rol M L, et al. Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions:a systematic literature review and meta-analysis[J]. Br J Cancer, 2024, 130(4):517-525. doi:10.1038/s41416-023-02490-w.
[20]	Xu F, Ran T, Wei Q, et al. Diagnostic value of HPV E6/E7 mRNA in screening for cervical intraepithelial neoplasia grade 2 or worse:a systematic review and meta-analysis[J]. Oncol Lett, 2024, 27(5):231. doi:10.3892/ol.2024.14364.
[21]	Mathews C S, Sargent A, Cuschieri K, et al. HPValidate-human papillomavirus testing with DNA and mRNA assays on self-collected samples in cervical screening:comparison of test characteristics on three self-sampling devices[J]. Br J Cancer, 2025, 133(5):665-673. doi:10.1038/s41416-025-03102-5.
[22]	Granados R, Duarte J A, Luján D R, et al. RNA extended interventional nucleic acid longitudinal study:clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9-year follow-up[J]. Cancer Cytopathol, 2024, 132(12):757-767. doi:10.1002/cncy.22895.
[23]	Bruno M T, Cassaro N, Vitale S G, et al. Possible role of negative human papillomavirus E6/E7 mRNA as a predictor of regression of cervical intraepithelial neoplasia 2 lesions in hr-HPV positive women[J]. Virol J, 2022, 19(1):95. doi:10.1186/s12985-022-01822-1.
[24]	Sørbye S, Falang B M, Antonsen M, et al. Genotype-specific HPV mRNA triage improves CIN2+ detection efficiency compared to cytology:a population-based study of HPV DNA-positive women[J]. Pathogens, 2025, 14(8):749. doi:10.3390/pathogens14080749.
[25]	Zhao C, Li M, Chen R, et al. Comparison of different mRNA testing technologies with HPV DNA testing for predicting ASCUS triage and post-cone excision outcomes:a systematic review and meta-analysis[J]. Syst Rev, 2026, 15(1):53. doi:10.1186/s13643-025-02947-4.
[26]	Carcea F, Daniilidis A, Vavoulidis E, et al. A cohort retrospective study of high-risk HPV recurrence in Greek women after cervical lesion treatment through detection of viral E6/E7 mRNA expression[J]. J BUON, 2020, 25(1):99-107.
[27]	Loayza A, Hernandez A, Rodriguez A M, et al. HPV E6/E7 mRNA testing in the follow-up of HPV-vaccinated patients after treatment for high-grade cervical intraepithelial neoplasia[J]. Vaccines(Basel), 2025, 13(8):823. doi:10.3390/vaccines13080823.
[28]	董伟, 刘勇, 李淑霞, 等. 妊娠期宫颈高级别鳞状上皮内病变的进展转归及对妊娠结局的影响[J]. 中华围产医学杂志, 2020, 23(5):330-337.
	Dong W, Liu Y, Li S X, et al. Prognosis of cervical high-grade squamous intraepithelial lesion in pregnancy and its effect on pregnancy outcome[J]. Chin J Perinat Med, 2020, 23(5):330-337. doi:10.3760/cma.j.cn113903-20190416-00265.
[29]	杨咏梅, 王凤英, 廖秦平, 等. 高危型人乳头瘤病毒E6/E7 mRNA在妊娠期高级别宫颈病变中的应用研究[J]. 北京医学, 2022, 44(4):287-291.
	Yang Y M, Wang F Y, Liao Q P, et al. Application of HR-HPV E6 and E7 mRNA detection in the management of high grade cervical lesions during pregnancy[J]. Beijing Med J, 2022, 44(4):287-291. doi:10.15932/j.0253-9713.2022.04.001.
[30]	胡晓军, 尤小燕, 周颖. HPV E6/E7 mRNA联合年龄在宫颈癌筛查HPV-DNA阳性分流中的作用研究[J]. 医药论坛杂志, 2024, 45(23):2493-2497.
	Hu X J, You X Y, Zhou Y. Study on role of HPV E6/E7 mRNA combined with age in screening HPV-DNA positive shunt for cervical cancer[J]. Journal of Medical Forum, 2024, 45(23):2493-2497. doi:10.20159/j.cnki.jmf.2024.23.007.
[31]	Bruno M T, Cavallaro A G, Sudano M C, et al. Role of endocervical curettage in detecting CIN2 + in postmenopausal women with persistent high-risk HPV and type 3 transformation zone[J]. BMC Cancer, 2025, 25(1):1486. doi:10.1186/s12885-025-14868-5.
[32]	Richter K L, Snyman L C, Dreyer G, et al. Aptima HPV E6/E7 mRNA and cytology cross-sectional performance as primary screening tests for detection of high-grade cervical lesions in HIV positive and negative women in South Africa[J]. J Med Screen, 2025, 32(3):133-140. doi:10.1177/09691413251317926.
[33]	Ratnam S, Coutlee F, Fontaine D, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer[J]. J Clin Microbiol, 2010, 48(8):2779-2785. doi:10.1128/JCM.00382-10.
[34]	Nkwinika V V, Amissah K A, Rakgole J N, et al. APTIMA mRNA vs. DNA-based HPV assays:analytical performance insights from a resource-limited South African setting[J]. Int J Mol Sci, 2025, 26(15):7450. doi:10.3390/ijms26157450.
[35]	U.S. Food and Drug Administration. Summary of safety and effectiveness data:APTIMA HPV assay:PMA No. P100042[R/OL]. (2011-10-28)[2026-05-07]. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100042b.pdf.
[36]	World Health Organization. Affordability of screen and treat tools for cervical cancer:Version 3[R/OL]. (2024-07-31)[2026-04-07]. https://cdn.who.int/media/docs/default-source/cervical-cancer/hpv-pricing-slides-2024.pdf.
[37]	广州市宝创生物技术有限公司. Aptima HPV E6/E7 mRNA 检测试剂盒产品介绍[EB/OL]. [2026-03-17]. https://www.ebiotron.com/cn/product/158.html.
	Guangzhou Baobio Biotechnology Co., Ltd. Product introduction of Aptima HPV E6/E7 mRNA detection kit[EB/OL]. [2026-03-17]. https://www.ebiotron.com/cn/product/158.html.
[38]	Liu T, Zhou X, Tao X, et al. Optimization of RNAscope for HPV mRNA detection in liquid-based cervical cytology samples[J]. Front Oncol, 2026, 16:1766237. doi:10.3389/fonc.2026.1766237.